GlaxoSmithKline forms Target Discovery Alliance in Asthma with Galapagos
January 05, 2005 08:00 ET | Galapagos NV
"We are excited that we have now partnered our asthma program with the leading player in this disease area" said Onno van de Stolpe, CEO of Galapagos. "The licensing of our targets to GSK is a...
Graham Dixon joins Galapagos as Chief Scientific Officer
November 30, 2004 02:00 ET | Galapagos NV
About Galapagos Genomics NVGalapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma.  Proprietary...
Celgene and Galapagos Enter Target Discovery Collaboration
November 18, 2004 07:00 ET | Galapagos NV
Under the terms of the agreement, Galádeno (Galapagos' wholly owned services unit) will provide Celgene with its adenoviral siRNA and cDNA libraries, SilenceSelect (TM) and FLeXSelect (TM). ...
Wyeth selects novel drug targets in osteoporosis collaboration with Galapagos
November 09, 2004 02:00 ET | Galapagos NV
"We are excited that we have successfully delivered on our commitments in our osteoporosis program with Wyeth.  The selection of these targets is a critical decision as it forms the basis for the...
Galapagos appoints Raj Parekh as Chairman and Wilson Totten to Board of Directors
October 05, 2004 02:00 ET | Galapagos NV
"I am very pleased to have both Raj Parekh and Wilson Totten join our board at this time," said Onno van de Stolpe, Chief Executive Officer. "Their experience in building major biotechnology companies...
Galapagos announces the separation of its drug discovery and target discovery service - forms Galádeno(TM) as an independent business unit
September 22, 2004 08:00 ET | Galapagos NV
Mechelen, Belgium, September 22nd, 2004 - Galapagos Genomics NV, Europe's leading target discovery company, announced today that it has created a new business unit for its viral based discovery and...
Galapagos reports success in identification and validation of proprietary drug targets and moves into drug discovery.
June 07, 2004 02:00 ET | Galapagos NV
Mechelen, Belgium, June 7th, 2004 -- Galapagos Genomics NV, Europe's leading target discovery company, announced today that it has identified, validated and filed patent applications on several novel...
Galapagos Receives Grant for Alzheimer's Disease Research
February 12, 2004 02:00 ET | Galapagos NV
Galapagos will build a number of Alzheimer's Disease relevant assays using neuronal cells and will use these in combination with its adenoviral based target discovery platform.  ...
Bayer Healthcare and Galapagos in Target Discovery Collaboration
December 16, 2003 02:00 ET | Galapagos NV
Mechelen, Belgium, December 16, 2003 - Galapagos Genomics today announced a target discovery collaboration with Bayer HealthCare AG.  Within the partnership, the Companies will collaborate to...
Wyeth Pharmaceuticals and Galapagos form Discovery Alliance in Osteoporosis
November 13, 2003 02:00 ET | Galapagos NV
Mechelen, Belgium, November 13, 2003 -Galapagos Genomics today announced that it has entered into a discovery alliance in the field of osteoporosis with Wyeth Pharmaceuticals, the pharmaceutical...